Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
81. |
ECCT/24/12/01 | PDMC-Saves Lives (PDMC-SL) Delivery strategies for malaria chemoprevention in the post-discharge management of hospitalised children with severe anaemia or severe malaria: cluster and individually randomised controlled implementation trials with nested economic evaluation in Kenya and Benin |
Principal Investigator(s) 1. Juliet Otieno Awori 2. Simon Kariuki Site(s) in Kenya Health facilities with blood transfusion services in malaria-endemic areas in Western Kenya |
16-04-2025 |
View |
82. |
ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. |
Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
21-05-2025 |
View |
83. |
ECCT/25/03/01 | MK-5684_MSD (mCRPC) A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) |
Principal Investigator(s) 1. PROF MANSOOR NOORALI SALEH Site(s) in Kenya AGA KHAN UNIVERSITY HOSPITAL NAIROBI |
20-05-2025 |
View |
84. |
ECCT/24/11/03 | REALISE STUDY PROTOCOL A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children |
Principal Investigator(s) 1. Alejandro Javier Krolewiecki Site(s) in Kenya Kwale county |
19-06-2025 |
View |
85. |
ECCT/24/11/01 | Sparkle A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Site 1401:Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402:Ahero Clinical trials Unit (Kisumu county) 3. Site 1403:International Cancer institute (Uasin Gishu county) 4. Site 1404:Kondele Childrens Hospital (Kisumu county) 5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county) 6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county) |
13-05-2025 |
View |
86. |
ECCT/24/10/04 | Cabotegravir + Rilpivirine Inj A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Aga Khan University Hospital Nairobi (Nairobi City county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
30-04-2025 |
View |
87. |
ECCT/25/02/11 | Extended Dosing OCV Trial A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, Kenya |
Principal Investigator(s) 1. Samuel Kariuki Site(s) in Kenya MMM MUKURU HEALTH CENTRE |
16-07-2025 |
View |
88. |
ECCT/24/10/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county) |
12-11-2024 |
View |
89. |
ECCT/24/10/01 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Videlis Nduba Nzioka Site(s) in Kenya 1. KEMRI-CRDR Clinical Research Annex (Nairobi City county) 2. Clinical Research Health Network (CREA-N) (Machakos county) 3. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 4. KEMRI-Mtwapa Clinical Annex (Kilifi county) 5. University of Nairobi Clinical Research Centre (Nairobi City county) |
21-12-2024 |
View |
90. |
ECCT/24/10/03 | EDE Scanner Study A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria |
Principal Investigator(s) 1. VIDELIS Nduba 2. Berngards Ogutu Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI/CRDR Siaya Clinical trials Annex (Siaya county) 3. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county) |
07-04-2025 |
View |